CWM
GILD icon

Concert Wealth Management’s Gilead Sciences GILD Stock Holding History

Concert Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-100
Closed -$3K – 648
2016
Q3 		$3K Sell
100
-800
-89% -$65K ﹤0.01% 985
2016
Q2 		$3K Buy
+900
New +$79.9K ﹤0.01% 677

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Concert Wealth Management's GILD Position: Q2 2017 in Review

Concert Wealth Management sold out of Gilead Sciences (GILD) in Q2 2017, closing a stake of 18,578 shares — an estimated $1.33M sold.

Concert Wealth Management first reported a position in GILD in Q2 2013 and held it in 16 quarters. The position peaked at $2.71M in Q2 2016. 1,520 funds tracked by Wall St. Rank hold GILD as of Q2 2017.

  • Concert Wealth Management reported no remaining Gilead Sciences position as of Q2 2017 after selling out during the quarter.
  • Concert Wealth Management sold 18,578 Gilead Sciences shares in Q2 2017, an estimated $1.33M.
  • Concert Wealth Management first reported a position in Gilead Sciences in Q2 2013 and held it in 16 quarters.
  • Concert Wealth Management's Gilead Sciences position peaked at $2.71M in Q2 2016.
  • 1,520 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2017.

Based on Concert Wealth Management's 13F filing for Q2 2017, filed 10 Aug 2017.